All In Biotech

NDA 008453 · Sandoz

Anectine

Succinylcholine Chloride · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1952

Aug 20, 1952

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

13 Phase 3, 4 recruiting

FAERS reports

2,145

1,809 serious, 252 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS • Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy [see Warnings and Precautions (5.1) ] . • When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of ANECTINE not felt to be due to inadequate ventilation, oxygenation, or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. In the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently [see Warnings and Precautions (5.1) ] . •...

What it is approved for

From the label in effect Nov 29, 2023.

ANECTINE is indicated in adults and pediatric patients: • as an adjunct to general anesthesia • to facilitate tracheal intubation • to provide skeletal muscle relaxation during surgery or mechanical ventilation. ANECTINE is a depolarizing neuromuscular blocker indicated in adults and pediatric patients: • as an adjunct to general anesthesia ( 1 ) • to facilitate tracheal intubation ( 1 ) • to provide skeletal muscle relaxation during surgery or mechanical ventilation ( 1 ).

Mechanism: Succinylcholine is a depolarizing neuromuscular blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the receptor site. Onset of flaccid paralysis is rapid (less than one minute after intravenous administration), and with single administration lasts approximately 4 to 6 minutes. The paralysis following administration of succinylcholine is progressive,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 20, 1952 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • ANECTINE · SUCCINYLCHOLINE CHLORIDE 1GM/VIAL · INJECTABLE, INJECTION · Discontinued
  • ANECTINE · SUCCINYLCHOLINE CHLORIDE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • ANECTINE · SUCCINYLCHOLINE CHLORIDE 50MG/ML · INJECTABLE, INJECTION · Discontinued
  • ANECTINE · SUCCINYLCHOLINE CHLORIDE 500MG/VIAL · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Succinylcholine Chloride" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective249
  • hypotension184
  • cardiac arrest164
  • anaphylactic shock147
  • drug interaction127
  • renal failure118
  • pain114
  • anaphylactic reaction112
  • renal impairment106
  • anxiety102
  • injury101
  • hyperthermia malignant98

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200493
200532
200644
200751
200853
200958
201074
2011208
201296
201332
201425
201557
201674
201794
201892
2019158
2020156
2021133
2022131
2023125
2024106
2025162
202691

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.